Findings

What do systematic reviews say?

11 questions · 11 findings · 6 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 18.2%GRADE not reported 1 · 9.1%Very low 8 · 72.7%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

VALPROATE + ANTIPSYCHOTICS vs placebo/no adjunctive treatment + antipsychotics

Acceptability of treatment ‐ leaving the study early · patients with schizophrenia

It is very uncertain whether VALPROATE + ANTIPSYCHOTICS changes leaving the study early: Acceptability of treatment Leaving the… compared with ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone (very low certainty).

1 finding from 1 review

Valproate for schizophrenia 2016 · Cochrane Headline outcomes only
RR 0.76 [0.47, 1.24]
11 studies · 951 participants
Very low

Reduced dose of antipsychotics vs antipsychotic maintenance

Leaving the study early · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia

It is very uncertain whether reduced dose of antipsychotics changes acceptability of the treatment: leaving the study early compared with antipsychotic maintenance (very low certainty).

1 finding from 1 review

Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia 2018 · Cochrane Headline outcomes only
RR 0.33 [0.06, 1.99]
1 study · 8 participants
Very low

Adjunctive carbamazepine + antipsychotics vs placebo/no adjunctive treatment + antipsychotics

Leaving the study early · patients with schizophrenia

It is very uncertain whether adjunctive carbamazepine + antipsychotics changes acceptability of treatment Leaving the study early due to any reason compared with placebo/no adjunctive treatment + antipsychotics (very low certainty).

1 finding from 1 review

Carbamazepine for schizophrenia 2014 · Cochrane Headline outcomes only
RR 0.47 [0.16, 1.35]
8 studies · 182 participants
Very low

ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS vs placebo/no adjunctive treatment + antipsychotics

Unacceptability of treatment (drop-outs / leaving study early) · patients with schizophrenia

It is very uncertain whether ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS changes leaving the study early due to any reason (overall acceptability of… compared with PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS (very low certainty).

1 finding from 1 review

Benzodiazepines for schizophrenia 2012 · Cochrane Headline outcomes only
RR 1.36 [0.81, 2.3]
19 studies · 1185 participants
Very low

ECT plus standard care vs antipsychotics plus standard care

Satisfaction with treatment: leaving the study early Endpoint data (events) · people with treatment‐resistant schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Electroconvulsive therapy for treatment‐resistant schizophrenia 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

ECT alone vs antipsychotics

Satisfaction with treatment: leaving the study early Endpoint data (events) · people with treatment‐resistant schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Electroconvulsive therapy for treatment‐resistant schizophrenia 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

FLUPENTHIXOL vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

Acceptability of treatment ‐ leaving the study early · patients with schizophrenia

1 finding from 1 review

Flupenthixol versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Switch to another antipsychotic vs antipsychotic cessation

Leaving the study early · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether switch to another antipsychotic changes acceptability of the treatment: leaving the study early compared with antipsychotic cessation (very low certainty).

1 finding from 1 review

Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia 2018 · Cochrane Headline outcomes only
RR 0.6 [0.16, 2.25]
1 study · 50 participants
Very low

Switch to a specific antipsychotic vs switch to a different specific antipsychotic

Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia

1 finding from 1 review

Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia 2018 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 466 participants
Very low

Specific antipsychotic vs other drugs

Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether specific antipsychotic changes acceptability of the treatment: leaving the study early compared with other drugs (very low certainty).

1 finding from 1 review

Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia 2018 · Cochrane Headline outcomes only
RR 4.38 [0.25, 76.54]
1 study · 13 participants
Very low

Benzodiazepines vs antipsychotics

Unacceptability of treatment (drop-outs / leaving study early) · patients with schizophrenia

It is very uncertain whether BENZODIAZEPINES changes leaving the study early due to any reason (overall acceptability of… compared with ANTIPSYCHOTICS (very low certainty).

1 finding from 1 review

Benzodiazepines for schizophrenia 2012 · Cochrane Headline outcomes only
RR 0.73 [0.45, 1.18]
13 studies · 738 participants
Very low